Ocugen (OCGN)

Last close As at 09/01/2026

USD1.50

0.01 (0.67%)

Market capitalisation

USD466m

Ocugen is a clinical-stage biotechnology company developing novel gene therapies to treat blinding retinal diseases, and its subsidiary is advancing cell therapies for orthopaedic indications.

Latest Insights

Healthcare | Quickview

Ocugen — Novel cell therapies for retinal diseases

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Shankar Musunuri

    CEO

  • Ramesh Ramachandran

    Chief Accounting Officer